全文获取类型
收费全文 | 224篇 |
免费 | 6篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 3篇 |
妇产科学 | 4篇 |
基础医学 | 23篇 |
临床医学 | 20篇 |
内科学 | 52篇 |
皮肤病学 | 3篇 |
神经病学 | 7篇 |
特种医学 | 1篇 |
外科学 | 43篇 |
综合类 | 1篇 |
预防医学 | 10篇 |
眼科学 | 2篇 |
药学 | 31篇 |
中国医学 | 3篇 |
肿瘤学 | 32篇 |
出版年
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 7篇 |
2020年 | 3篇 |
2019年 | 6篇 |
2018年 | 1篇 |
2017年 | 4篇 |
2016年 | 10篇 |
2015年 | 5篇 |
2014年 | 8篇 |
2013年 | 13篇 |
2012年 | 26篇 |
2011年 | 12篇 |
2010年 | 15篇 |
2009年 | 10篇 |
2008年 | 23篇 |
2007年 | 13篇 |
2006年 | 19篇 |
2005年 | 7篇 |
2004年 | 7篇 |
2003年 | 10篇 |
2002年 | 4篇 |
2001年 | 2篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1971年 | 2篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1935年 | 1篇 |
排序方式: 共有237条查询结果,搜索用时 15 毫秒
231.
232.
233.
234.
Hons J Vasatova M Cermakova E Doubek P Libiger J 《Journal of psychiatric research》2012,46(6):811-818
Dysfunction of the N-methyl-d-aspartate receptor, which is modulated by excitatory amino acids (EAA), is involved in the pathophysiology of schizophrenia. The effects of antipsychotics on EAA metabolism are uncertain. Positive clinical effects of treatment with antipsychotics were not always associated with changes in EAA serum levels in patients with schizophrenia in clinical trials. To examine EAA serum levels in relation to the intensity of psychotic symptoms and the type of medication received we compared these variables among patients with schizophrenia (n = 49) treated with first (FGA) or second (SGA) generation antipsychotics or clozapine. Glutamate, aspartate, glycine, total serine and d-serine serum levels were measured by High Performance Liquid Chromatography. The Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS) were used to assess symptoms of schizophrenia. Lower average levels of glycine and total serine were found in the serum of patients receiving clozapine when compared to the groups of patients treated with FGA or SGA. There were no differences in serum glutamate, aspartate or d-serine levels or in the intensity of schizophrenic symptoms assessed by PANSS or SANS among the groups of patients treated with FGA or SGA or clozapine. Lower glycine and total serine serum levels could be caused by the particular characteristics of the population of patients receiving clozapine rather than as an effect of the clozapine. The results suggest selective deficiency of l-serine synthesis in the patients with resistance to non-clozapine treatment. It might be an unique biochemical and pathophysiological characteristic of the treatment-resistance in schizophrenia. 相似文献
235.
Beldie A den Boer JA Brain C Constant E Figueira ML Filipcic I Gillain B Jakovljevic M Jarema M Jelenova D Karamustafalioglu O Kores Plesnicar B Kovacsova A Latalova K Marksteiner J Palha F Pecenak J Prasko J Prelipceanu D Ringen PA Sartorius N Seifritz E Svestka J Tyszkowska M Wancata J 《Social psychiatry and psychiatric epidemiology》2012,47(Z1):1-38
236.
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window 总被引:5,自引:0,他引:5
Koschny R Ganten TM Sykora J Haas TL Sprick MR Kolb A Stremmel W Walczak H 《Hepatology (Baltimore, Md.)》2007,45(3):649-658
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) represents a novel promising anticancer biotherapeutic. However, TRAIL-resistant tumor cells require combinatorial regimens to sensitize tumor but not normal cells for TRAIL-induced apoptosis. Here, we investigated the mechanism of the synergistic antitumor effect of bortezomib in combination with TRAIL in hepatoma, colon, and pancreatic cancer cells in comparison to the toxicity in primary human hepatocytes (PHH). TRAIL cotreatment at high but clinically relevant concentrations of bortezomib caused toxicity in PHH which potentially limits the clinical applicability of bortezomib/TRAIL cotreatment. However, at low concentrations of bortezomib TRAIL-resistant hepatoma, colon and pancreatic cancer cell lines but not PHH were efficiently sensitized for TRAIL-induced apoptosis. RNA interference and TRAIL receptor blockage experiments revealed that in bortezomib-treated hepatoma cells TRAIL-R1/TRAIL-R2 up-regulation, enhanced TRAIL DISC formation and cFLIPL down-regulation in addition to accumulation of Bak cooperatively sensitized for TRAIL. Bim, although accumulated upon bortezomib treatment, did not play a causal role for TRAIL sensitization in Hep3b cells. Combined treatment with bortezomib and TRAIL massively reduced the clonogenic capacity of hepatoma cells in vitro. Surviving clones could be resensitized for repeated TRAIL treatment. CONCLUSION: Bortezomib/TRAIL cotreatment bears the risk of severe hepatotoxicity at high but clinically relevant concentrations of bortezomib. However, within a wide therapeutic window bortezomib sensitized different cancer cells but not PHH for TRAIL-induced apoptosis. 相似文献
237.